(Q40285757)

19 September 2017

Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali (English)

1 reference

19 September 2017

0 references

0 references

1 reference

1 reference

4

Amadou A Sall

1 reference

19 September 2017

5

Samba Sow

1 reference

19 September 2017

Mariam Sidibe

1

1 reference

19 September 2017

Sergio Yactayo

2

1 reference

19 September 2017

Abdoulaye Kalle

3

1 reference

19 September 2017

Modjirom Ndoutabe

6

1 reference

19 September 2017

William Perea

7

1 reference

19 September 2017

Fenella Avokey

8

1 reference

19 September 2017

Rosamund F Lewis

9

1 reference

19 September 2017

Olivia Veit

10

1 reference

19 September 2017

22 May 2012

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

19 September 2017

1 reference

19 September 2017

106

1 reference

19 September 2017

7

1 reference

19 September 2017

437-444

1 reference

19 September 2017

Yellow fever: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Acute viscerotropic disease following vaccination against yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Safety of 17D derived yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Yellow fever vaccine is safe and effective in HIV-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

The 1987 yellow fever epidemic in Mali: viral and immunological diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Predictors of immunity after hepatitis A vaccination in HIV-infected persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Infections in HIV-infected travelers: risks and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

Vaccination in Brazilian HIV-infected adults: a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2012.04.002

10.1016/J.TRSTMH.2012.04.002

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference